Hero N° 03 sits inside the mood category — one of sixteen launches in a portfolio built around modern science layered onto inherited ritual.
Each hero in the portfolio is a deliberate bet on a specific consumer shift: away from default Western formats, toward functional, ingredient-honest products with provable mechanisms. This page is the public-facing brief. The full thesis — formulation, unit economics, supply chain, founder background — lives behind the deal-room door.
Anxiety is the default state of the consumer base. Pharmaceutical answers are over-prescribed; the wellness shelf is over-promising and under-dosing.
The 4pm dip. The Sunday-night dread. The moment a consumer reaches for something — and the choice is currently a glass of wine or an edible.
Adaptogenic and nootropic CPG is forecast to outpace conventional supplements by 3× through 2030. Most incumbents are repackaged multivitamins.
The functional-wellness native who has tried mushrooms, magnesium, and microdosing — and is looking for something with a real mechanism.
We do not invent rituals. We replace the product inside one. Each hero in the portfolio sits on a specific, repeatable moment in the consumer's day — one the incumbent has owned for a generation and is now losing.
01
16:00
The dip
Cortisol crashes, attention fragments, willpower thins. Whatever sits in the desk drawer at 4pm owns the rest of the workday.
02
19:00
The transition
The moment work-self becomes home-self. Currently mediated by a glass of wine. Wide open for a non-alcoholic, mechanism-led alternative.
03
Sun · 21:00
The dread
Sunday-night anxiety is a $4B occasion the wellness shelf has not credibly answered.
The incumbent shelf
- —Calm app subscriptions
- —OTC magnesium
- —Cannabis edibles
- —Wine and spirits
The new wave
- +Clinical-dose adaptogens
- +Functional mushroom RTDs
- +Non-alcoholic mood drinks
- +Single-ingredient nootropic CPG
"Mood is the next vertical to professionalise. Currently sold by influencers; will be sold by clinicians within five years."
$143B ready-meal market globally, $11B in 'functional' subsegment.
Daily Harvest raised at $1.1B before stumbling on supply chain. Methodology, Factor75 (sold to HelloFresh for $277M) all proved DTC ready-meal works. None segment by mood — they segment by diet (keto, paleo, vegan), which is a saturated lane.
The product specifics — the proprietary formulation, the brand architecture, the channel strategy, the unit economics — are deliberately not on this page. We don't publish the recipe to the open internet.
- Full formulation & ingredient stack
- Clinical and mechanism-of-action references
- Founder thesis and category positioning
- Unit economics and pricing model
- Supply chain and manufacturing partner
- Go-to-market plan and channel mix
- How is this different from supplements?
- Most supplements compete on count and price. Mood-CPG competes on mechanism, dose, and ritual. Different shelf, different buyer, different unit economics.
- Is this regulated?
- Operates under DSHEA in the US with conservative claims; full regulatory and IP positioning available in the deal-room.
- What about the cannabis crossover?
- We treat cannabis as adjacent, not competitive. The non-intoxicating mood occasion is structurally larger and more broadly distributable.
The next move.
The investor deck, unit economics, and a direct line to the founder live behind the deal-room door. Or stay close to the portfolio with a monthly subscriber drop — first look on every new SKU.
